40 related articles for article (PubMed ID: 11509597)
1. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population.
Karnbach C; Daws MR; Niemi EC; Nakamura MC
J Immunol; 2001 Sep; 167(5):2569-76. PubMed ID: 11509597
[TBL] [Abstract][Full Text] [Related]
2. Rapid development of a gamma interferon-secreting glycolipid/CD1d-specific Valpha14+ NK1.1- T-cell subset after bacterial infection.
Emoto M; Yoshizawa I; Emoto Y; Miamoto M; Hurwitz R; Kaufmann SH
Infect Immun; 2006 Oct; 74(10):5903-13. PubMed ID: 16988270
[TBL] [Abstract][Full Text] [Related]
3. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.
Matsuda JL; Naidenko OV; Gapin L; Nakayama T; Taniguchi M; Wang CR; Koezuka Y; Kronenberg M
J Exp Med; 2000 Sep; 192(5):741-54. PubMed ID: 10974039
[TBL] [Abstract][Full Text] [Related]
4. Effects of macrophage-colony-stimulating factor on cyclophosphamide-injected mouse NK1.1+ cell activity.
Sakurai T; Misawa E; Yamada M; Hayasawa H; Motoyoshi K
Cancer Immunol Immunother; 2000 May; 49(2):94-100. PubMed ID: 10823419
[TBL] [Abstract][Full Text] [Related]
5. Isolation of murine hepatic lymphocytes using mechanical dissection for phenotypic and functional analysis of NK1.1+ cells.
Dong ZJ; Wei HM; Sun R; Tian ZG; Gao B
World J Gastroenterol; 2004 Jul; 10(13):1928-33. PubMed ID: 15222039
[TBL] [Abstract][Full Text] [Related]
6. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
7. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
Ghiringhelli F; Menard C; Puig PE; Ladoire S; Roux S; Martin F; Solary E; Le Cesne A; Zitvogel L; Chauffert B
Cancer Immunol Immunother; 2007 May; 56(5):641-8. PubMed ID: 16960692
[TBL] [Abstract][Full Text] [Related]
8. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity.
Berzofsky JA; Terabe M
Cancer Immunol Immunother; 2008 Nov; 57(11):1679-83. PubMed ID: 18369622
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.
Pegram HJ; Haynes NM; Smyth MJ; Kershaw MH; Darcy PK
Cancer Immunol Immunother; 2010 Aug; 59(8):1235-46. PubMed ID: 20376439
[TBL] [Abstract][Full Text] [Related]
10. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis.
Katsanis E; Bausero MA; Ochoa AC; Loeffler CM; Blazar BR; Leonard AS; Anderson PM
Cancer Immunol Immunother; 1991; 34(2):74-8. PubMed ID: 1760819
[TBL] [Abstract][Full Text] [Related]
11. Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.
Kedar E; Ben-Aziz R; Epstein E; Leshem B
Cancer Immunol Immunother; 1989; 29(1):74-8. PubMed ID: 2785003
[TBL] [Abstract][Full Text] [Related]
12. Production and enhanced anti-tumor activity of tumor necrosis factor in mice treated with cyclophosphamide.
Noso Y; Becker J; Riveau G; Audibert F; Chedid L
Jpn J Cancer Res; 1990 Sep; 81(9):942-8. PubMed ID: 2121696
[TBL] [Abstract][Full Text] [Related]
13. NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy.
Gao JQ; Tsuda Y; Han M; Xu DH; Kanagawa N; Hatanaka Y; Tani Y; Mizuguchi H; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
Cancer Immunol Immunother; 2009 Feb; 58(2):291-9. PubMed ID: 18629495
[TBL] [Abstract][Full Text] [Related]
14. Development of a cancer DNA phenotype prior to tumor formation.
Malins DC; Anderson KM; Gilman NK; Green VM; Barker EA; Hellström KE
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10721-5. PubMed ID: 15249662
[TBL] [Abstract][Full Text] [Related]
15. CCR5 drives NK cell-associated airway damage in pulmonary ischemia-reperfusion injury.
Santos J; Wang P; Shemesh A; Liu F; Tsao T; Aguilar OA; Cleary SJ; Singer JP; Gao Y; Hays SR; Golden JA; Leard L; Kleinhenz ME; Kolaitis NA; Shah R; Venado A; Kukreja J; Weigt SS; Belperio JA; Lanier LL; Looney MR; Greenland JR; Calabrese DR
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37788115
[TBL] [Abstract][Full Text] [Related]
16. Prospects for NK Cell Therapy of Sarcoma.
Lachota M; Vincenti M; Winiarska M; Boye K; Zagożdżon R; Malmberg KJ
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322371
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.
Calabrese DR; Aminian E; Mallavia B; Liu F; Cleary SJ; Aguilar OA; Wang P; Singer JP; Hays SR; Golden JA; Kukreja J; Dugger D; Nakamura M; Lanier LL; Looney MR; Greenland JR
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33290276
[TBL] [Abstract][Full Text] [Related]
18. Role of Interleukin-12 in Protection against Pulmonary Infection with Methicillin-Resistant Staphylococcus aureus.
Nguyen QT; Furuya Y; Roberts S; Metzger DW
Antimicrob Agents Chemother; 2015 Oct; 59(10):6308-16. PubMed ID: 26248370
[TBL] [Abstract][Full Text] [Related]
19. SJSZ glycoprotein (38 kDa) modulates expression of IL-2, IL-12, and IFN-γ in cyclophosphamide-induced Balb/c.
Lee J; Lim KT
Inflamm Res; 2012 Dec; 61(12):1319-28. PubMed ID: 22814394
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
